NDA 022165 · Cosette
Cambia
Diclofenac Potassium · Oral
Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Jun 17, 2009
Approved uses
1
Original approval plus efficacy supplements
Registered trials
492
123 Phase 3, 29 recruiting
FAERS reports
10,696
8,489 serious, 4,383 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [ see Warnings and Precautions ( 5.1 ) ]. CAMBIA is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [ see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 ) ]. Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with...
What it is approved for
From the label in effect Dec 11, 2024.
CAMBIA is indicated for the acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Limitations of Use: CAMBIA is not indicated for the prophylactic therapy of migraine. The safety and effectiveness of CAMBIA have not been established for cluster headache, which is present in an older, predominantly male population. CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older ( 1 ) Limitations of Use ( 1 ): CAMBIA is not indicated for the prophylactic therapy of migraine Safety and effectiveness of CAMBIA not established for cluster headache, which is present in an older, predominantly male population
Mechanism: CAMBIA has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of CAMBIA, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro. Diclofenac concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because diclofenac is an inhibitor of prostaglandin synthesis, its...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 17, 2009 Original approval · Type 3 - New Dosage Form LabelSummary ReviewReview
1 products under this application
- CAMBIA · DICLOFENAC POTASSIUM 50MG · FOR SOLUTION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Diclofenac" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00250445 · 23,498 participants · Start Jan 2003 · Primary completion May 2006
Drug: MK0663, etoricoxib; Comparator: Diclofenac sodium · For: Rheumatoid Arthritis,Osteoarthritis
- The Standard Care Versus Celecoxib Outcome TrialPivotal-lookingCompleted
University of DundeeAcademic, hospital or other
NCT00447759 · 7,297 participants · Start Jun 2007 · Primary completion Aug 2015
Drug: Celecoxib; Diclofenac · For: Osteoarthritis; Rheumatoid Arthritis
Sites: Odense, Denmark; Zeist, Netherlands; Aberdeen, United Kingdom · 10 sites in all
- Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00092703 · 6,000 participants · Start Jun 27, 2002 · Primary completion Nov 1, 2003
Drug: MK0663, etoricoxib; Comparator: Diclofenac sodium · For: Osteoarthritis
- Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With ArthritisPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00141102 · 4,484 participants · Start Oct 2005 · Primary completion May 2009
Drug: Celecoxib; Diclofenac + Omeprazole · For: Osteoarthritis; Arthritis, Rheumatoid
Sites: Genk, Belgium; Ghent, Belgium; Hasselt, Belgium · 194 sites in all
- Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00092742 · 4,086 participants · Start Feb 2003 · Primary completion Dec 2005
Drug: MK0663, etoricoxib; Comparator: Diclofenac sodium · For: Rheumatoid Arthritis
- Indomethacin vs Diclofenac for Preventing PEPPivotal-lookingRecruiting
Air Force Military Medical University, ChinaAcademic, hospital or other
NCT07071441 · 4,050 participants (planned) · Start Jun 1, 2025 · Primary completion Dec 31, 2026
Drug: Indomethacin 100 MG; Diclofenac 100mg · For: ERCP; Pancreatitis; Non-steroidal Anti-inflammatory (NSAID) and 2 more
Sites: Beijing, China; Chongqing, China; Xiamen, China · 20 sites in all
- Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or KneePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02528188 · 3,021 participants · Start Jul 21, 2015 · Primary completion Oct 5, 2018
Drug: NSAID; Tanezumab 2.5 mg and 1 more · For: Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 507 sites in all
- Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or HipPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03304379 · 1,650 participants · Start Oct 26, 2017 · Primary completion Dec 13, 2019
Drug: Fasinumab; Matching placebo · For: Osteoarthritis, Knee; Osteoarthritis, Hip
Sites: Anniston, Alabama; Mobile, Alabama; Chandler, Arizona · 71 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective2,897
- rheumatoid arthritis2,674
- fatigue2,642
- off label use2,597
- pain2,541
- rash2,540
- systemic lupus erythematosus2,494
- joint swelling2,437
- wound2,383
- pemphigus2,317
- glossodynia2,295
- synovitis2,293
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 9 |
| 2006 | 59 |
| 2007 | 9 |
| 2008 | 16 |
| 2009 | 14 |
| 2010 | 15 |
| 2011 | 66 |
| 2012 | 45 |
| 2013 | 54 |
| 2014 | 71 |
| 2015 | 205 |
| 2016 | 894 |
| 2017 | 511 |
| 2018 | 486 |
| 2019 | 642 |
| 2020 | 597 |
| 2021 | 499 |
| 2022 | 689 |
| 2023 | 845 |
| 2024 | 2,081 |
| 2025 | 1,931 |
| 2026 | 954 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cambia (Diclofenac Potassium)
2024 spending
$1.3M
Beneficiaries
264
1,103 claims
Per beneficiary
$5,102
$93.21 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $7,032,916 |
| 2021 | $6,823,634 |
| 2022 | $6,277,481 |
| 2023 | $2,474,537 |
| 2024 | $1,347,019 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis.
da Costa BR, Pereira TV, Saadat P, et al. · BMJ 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
Santhosh A, Sharma A, Bakhshi S, et al. · J Clin Oncol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Diclofenac.
Ogle C · Conn Med 1989 · Clinical Trial, Randomized Controlled Trial
- Topical NSAIDs for acute musculoskeletal pain in adults.
Derry S, Moore RA, Gaskell H, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy and safety of simple analgesics for acute treatment of episodic tension-type headache in adults: a network meta-analysis.
Xie R, Li J, Jing Y, et al. · Ann Med 2024 · Systematic Review, Network Meta-Analysis
- Preventing Hand-Foot Syndrome in Patients With Cancer: A Systematic Review and Network Meta-Analysis.
Baskarane H, Sahni S, Nagpal C, et al. · JAMA Dermatol 2026 · Network Meta-Analysis, Systematic Review
Sponsor: Cosette
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.